Journal: bioRxiv

Article Title: Microengineered transplantation of human solid tumors for in vitro studies of CAR T immunotherapy

doi: 10.1101/2025.04.25.650709

Figure Lengend Snippet: a, Visualization of the interacting pairs of ITGAL-ICAM1 and CD38-PECAM1 in the meso-tumor model (left) and violin plots comparing the expression of interacting genes of interest mediating the crosstalk between CAR T cells and endothelial cells (right). b, Experimental timeline for CAR T cell infusion and drug treatment. c, Representative fluorescence micrographs of single meso-tumors infused with meso-CAR T cells without drug treatment (Untreated), treated with Daratumumab (0.5 or 10 μg/ml), or IgG isotype control antibody (10 μg/ml IgG). Blood vessels are not shown in these images. Scale bars, 250 μm. d,e, Quantification of T cell area ( d ) and normalized tumor area ( e ) over time. Data are presented as mean ± SEM (n ≥ 3). CAR T cells derived from one healthy donor were tested.

Article Snippet: The human CD38 inhibitor - Daratumumab (HY-P9915, MedChemExpress) and the lymphotoxin β receptor IgG fusion protein - Baminercept (HY-P99459, MedChemExpress) were used to inhibit the interactions between CD38 and its ligand PECAM1 and between lymphotoxin β and its receptor, respectively.

Techniques: Expressing, Fluorescence, Control, Derivative Assay

Journal: Cell

Article Title: Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

doi: 10.1016/j.cell.2020.08.002

Figure Lengend Snippet:

Article Snippet: CD38 , Fluidigm , Pro# 3167001B.

Techniques: Recombinant, Reverse Transcription, SYBR Green Assay, Staining, Functional Assay, Software

Journal: Nature Communications

Article Title: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth

doi: 10.1038/s41467-025-60456-3

Figure Lengend Snippet: a Flow cytometry analysis of CD200 (top) or tumor antigens (CD20, CD38, CD123, DLL3 and SLAMF7; bottom) on various human tumor cell lines. Red curves, CD200 mAb or tumor antigen-specific mAbs. Filled curves, Ctrl mAbs. b As per Fig. , except using IL-4-primed human blood monocyte-derived macrophages and human tumor cells in the presence of samalizumab (human IgG1, Fc-silent) or Ctrl mAb MOPC21 (human IgG1, Fc-silent). IgG opsonization was performed using CD20 mAb rituximab (SLVL, 721.221), CD38 mAb daratumumab (NCI-H929), CD123 mAb talacotuzumab (KG-1a), DLL3 mAb rovalpituzumab (NCI-H209), or SLAMF7 mAb elotuzumab (SK-MEL-28) ( n = 3 or 4). c As per Fig. 5b, except using the indicated cell lines and samalizumab (human IgG1, Fc-silent), CD47 mAb B6H12 (human IgG1, Fc-silent), or Ctrl mAb MOPC21 (human IgG1, Fc-silent). Tumor cells were opsonized as detailed for Fig. 5b, ( n = 3). d –f Subcutaneous injection of SLVL cells in NSG mice, followed by intraperitoneal injection of rituximab (mouse IgG2a version) combined with samalizumab or Ctrl mAb every 2 days, ( n = 8). d Schematic representation of the experimental workflow. e Tumor volume over time. f Tumor weight. g –i Subcutaneous injection of 721.221 cells in NSG mice, followed by intraperitoneal injection of rituximab (mouse IgG2a version) combined with samalizumab or Ctrl mAbs every 2 days, ( n = 10). g Schematic representation of the experimental workflow. h Tumor volume over time. i Tumor weight. Data are from three to four ( a, b ), three ( c ), or two ( d-i ) independent experiments. Each symbol represents one human sample or one mouse. Data are presented as mean ± s.e.m. Statistical analysis: two-tailed t-test ( f , i ), with multiple comparisons ( b, c , e , h ). ns, not significant. See also Supplementary Fig. .

Article Snippet: For cell opsonization, the following mAbs were used: Tac mAb 7G7 (BioXCell); human CD20 mAb rituximab biosimilar (BioXCell); human CD123 mAb talacotuzumab (MedChemExpress, Princeton, NJ); human CD38 mAb daratumumab (MedChemExpress); human DLL3 mAb rovalpituzumab (MedChemExpress).

Techniques: Flow Cytometry, Derivative Assay, Injection, Two Tailed Test

Journal: EMBO Molecular Medicine

Article Title: Mitochondrial damage drives T-cell immunometabolic paralysis after major surgery

doi: 10.1038/s44321-025-00324-1

Figure Lengend Snippet: ( A ) Scheme of the study flow and time points of blood withdrawal during the course of major surgery. ( B ) mRNA expression of IFNG (left), GZMB (middle) and PRF1 (right) in CTL (+CD3/CD28 dynabeads, stimulated for 18 h) relative to endogenous controls, n = 9/10/10 individual patients. ( C ) Flow cytometric analysis (FCA) of intracellular IFN-γ staining and quantification in CTL (+CD3/CD28 dynabeads, stimulated for 18 h; re-stimulation with PMA/Ionomycin for 4 h), n = 9 individual patients. ( D ) Quantification of IFN-γ secretion by CTL (+CD3/CD28 dynabeads, stimulated for 18 h), n = 9 individual patients. ( E ) Representative impedance plot (left) and quantification of relative CTL cytotoxicity (right) using ECIS, n = 7 individual patients. ( F ) FCA of CD38 staining and quantification in CTL, minimum = 28.6/32.9, 25%-percentile = 46.73/55.65, median = 59.65/67.05, 75%-percentile = 69.10/75.75, maximum = 75.10/80.60 (T1/T2), n = 10 individual patients. ( G ) Quantification of GZMB (left) and PRF1 (right) secretion by CTL (+CD3/CD28 dynabeads, stimulated for 18 h) as measured by ELISA, n = 11/12/6 (GZMB) and 13/13/6 (PRF1) individual patients. ( H ) FCA of intracellular GZMB staining and quantification in CTL (+CD3/CD28 dynabeads, stimulated for 18 h; re-stimulation with PMA/Ionomycin for 4 h), n = 9 individual patients. ( I ) FCA of intracellular PRF1 staining and quantification in CTL, n = 9 individual patients. ( J ) FCA of CD107a staining and quantification in CTL (+CD3/CD28 dynabeads, stimulated for 18 h; re-stimulation with PMA/Ionomycin for 4 h), n = 6 individual patients. If not stated otherwise, data are represented as mean ± SEM. P values as indicated, paired t -test or Wilcoxon matched-pairs signed-rank test, as appropriate. .

Article Snippet: CD38 APC , Miltenyi , 130-113-991.

Techniques: Expressing, Staining, Enzyme-linked Immunosorbent Assay

Journal: iScience

Article Title: Naive and memory CD4 + T cell subsets can contribute to the generation of human Tfh cells

doi: 10.1016/j.isci.2021.103566

Figure Lengend Snippet: CyTOF antibody panel

Article Snippet: Anti-Human CD38 (HIT2)- 144Nd , Fluidigm , Cat# 3144014B; RRID:AB_2687640.

Techniques:

Journal: iScience

Article Title: Naive and memory CD4 + T cell subsets can contribute to the generation of human Tfh cells

doi: 10.1016/j.isci.2021.103566

Figure Lengend Snippet: Selected genes involved in Tfh cell biology

Article Snippet: Anti-Human CD38 (HIT2)- 144Nd , Fluidigm , Cat# 3144014B; RRID:AB_2687640.

Techniques: Activation Assay

Journal: iScience

Article Title: Naive and memory CD4 + T cell subsets can contribute to the generation of human Tfh cells

doi: 10.1016/j.isci.2021.103566

Figure Lengend Snippet: Distinct CD4 + T cell subsets contribute to the generation of Tfh with heterogeneous functional profiles (A) Mean fluorescence intensity of the CXCR5 marker expressed by CXCR5 + PD-1 + cells derived from (1) naive, (2) MemPD-1 neg , (3) MemPD-1 neg and Tfh. (B) Frequency of IL-21- and/or IFNγ-positive cells among CXCR5 + PD-1 + cells at day 3. (C – E) Representative flow plots showing CXCR3, ICOS, and CD40L expression by CXCR5 + PD-1 + cells (left panel) and frequency of CXCR3-, ICOS-, and CD40L-positive cells among CXCR5 + PD-1 + cells at day 3 (right panel). (F) Ex vivo cells or their respective Tfh D3 counterparts obtained after 3 days of splenocyte culture were co-cultured with autologous B cells for 7 days. (G) Box plots represent the frequency of CD27 + CD38 + cells among CD19 + cells, the concentration of total immunoglobulins and the absolute number of live B cells after co-culture. (H) Quantification of IgG1, IgG4, and IgA in the co-culture supernatants. Each symbol (A–H) represents an individual donor. (A–H) A Wilcoxon matched pairs test was performed, ∗, p < 0.05; ∗∗, p < 0.005; ∗∗∗, p < 0.001.

Article Snippet: Anti-Human CD38 (HIT2)- 144Nd , Fluidigm , Cat# 3144014B; RRID:AB_2687640.

Techniques: Functional Assay, Fluorescence, Marker, Derivative Assay, Expressing, Ex Vivo, Cell Culture, Concentration Assay, Co-Culture Assay

Journal: iScience

Article Title: Naive and memory CD4 + T cell subsets can contribute to the generation of human Tfh cells

doi: 10.1016/j.isci.2021.103566

Figure Lengend Snippet: HIV infection shapes Tfh cell differentiation and functions (A) Splenocytes were stimulated according to the previously described protocol in the presence of HIV lab strain (Yu2b). (B) Representative flow plots of p24 staining among splenocytes after 3 days of culture with HIV or not. (C) RNA sequencing was performed on Tfh D3 cells derived from distinct CD4 + T cell subsets with and without HIV. Multidimensional scaling was performed to visually cluster different CD4 + T cell populations based on their transcriptional profile (8,593 genes). (D) RNA sequencing was performed on Tfh derived from each CD4 + T cell subset in the presence of HIV-1 infection or not. Differentially expressed genes were analyzed between Tfh and their original counterpart. Venn diagram representing (un)shared downregulated and upregulated genes. Genes specifically involved in Tfh cell biology were analyzed (referred to in ). (E) Contribution of each CD4 T cell subset to total Tfh generated after 3 days of splenocyte culture (%). Data are plotted as the mean percentage contribution of each ex vivo CD4 + T cell subset: (1) naive CD4 + T cells, (2) (3) memPD-1 neg/pos , and (4) Tfh to total Tfh D3 cells after splenocyte culture. (F) Representative flow plot of p24 staining in Tfh derived from distinct CD4 + T cell subsets. (G) Frequency of CD127-, CD27-, CD38-, FAS-, and ki67-positive cells among Tfh that are infected (p24 pos ) or not (p24 neg ). Each symbol (A–E) represents an individual donor. (E and G) A paired Student’s t test was performed, ∗p < 0.05, ∗∗p < 0.01. (F and G) A Wilcoxon matched pairs test was performed; ∗, p < 0.05; ∗∗, p < 0.005; ∗∗∗, p < 0.001.

Article Snippet: Anti-Human CD38 (HIT2)- 144Nd , Fluidigm , Cat# 3144014B; RRID:AB_2687640.

Techniques: Infection, Cell Differentiation, Staining, RNA Sequencing, Derivative Assay, Generated, Ex Vivo

Journal: iScience

Article Title: Naive and memory CD4 + T cell subsets can contribute to the generation of human Tfh cells

doi: 10.1016/j.isci.2021.103566

Figure Lengend Snippet:

Article Snippet: Anti-Human CD38 (HIT2)- 144Nd , Fluidigm , Cat# 3144014B; RRID:AB_2687640.

Techniques: Cell Analysis, Purification, Virus, Recombinant, Blocking Assay, Antibody Labeling, Transfection, Software

Journal: Frontiers in Immunology

Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging

doi: 10.3389/fimmu.2024.1383932

Figure Lengend Snippet: Immunophenotyping panel for multiplexed tissue imaging of cancer.

Article Snippet: CD38 , REA671 , 50 , 130-117-717 , PE (APC) , Miltenyi Biotec.

Techniques: Imaging

Journal: Frontiers in Immunology

Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging

doi: 10.3389/fimmu.2024.1383932

Figure Lengend Snippet: Deep spatial profiling of human palatine tonsil tissues. (A) Hematoxylin and eosin (H&E) staining after 92 MICS cycles, including the marked epithelium, germinal center (GC), and T cell zone of the lymphoid follicle. MICS DAPI and stroma staining depicting the composition and structure of the tonsil. Markers: Collagen III, collagen IV, fibronectin (all extracellular matrix (ECM), cytokeratin (epithelium), podoplanin (lymphatic vessels), CD105/SM Actin (blood vessels). (B) Immune cell content of a human palatine tonsil comprising T cells (CD3), B cells (CD19/CD20), plasma cells (PCs) (CD38/CD138), NK cells (CD56), granulocytes (CD15/CD66b), mast cells (CD117), macrophages (MΦ) (CD163/CD169/CD206), myeloid dendritic cells (mDCs) (CD11c), and plasmacytoid dendritic cells (pDCs) (CD123). (C) Detailed view on the T cell zone, mainly composed of CD4 + helper T cells (T h ) and CD8 + cytotoxic T cells (T c ), mDCs (CD11c), and PCs (CD38/CD138). (D) Detailed view on the GC-mantle zone border, showing different B cells (CD11b, CD21, CD22), mDCs (CD11c), and PCs (CD38/CD138). (E) Cell annotations of three different tonsil samples plus respective bar graphs of gated cell populations, comparing the cell content between the three tonsil samples. Depicted markers and annotated cell types as indicated by the color code. ROI sizes: 976 x 640 µm, zoomed-in subregions in (C, D) : 334 µm x 219 µm. Scale bar: 100 µm.

Article Snippet: CD38 , REA671 , 50 , 130-117-717 , PE (APC) , Miltenyi Biotec.

Techniques: Staining, Clinical Proteomics

Journal: Cancers

Article Title: Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1

doi: 10.3390/cancers13215508

Figure Lengend Snippet: The adenosine pathway in the LLC1 tumor microenvironment. ( A ) RNA was extracted from ASB-XIV and LLC1 tumor cells and subjected to RNA-Seq analysis. The mRNA expressions of immunosuppressive molecules in these two cell lines were shown. ( B ) The expressions of CD38, CD39, and CD73 on LLC1 were examined by flow cytometry in vitro. ( C ) C57BL/6 mice ( n = 5) received a subcutaneous injection of 5 × 10 5 LLC1. The combination of 2 mg/Kg A2A and 1 mg/Kg A2B adenosine receptor antagonists (SCH 58261 and PSB 1115) was administered on days 7, 9, 11, 13, 15, 17, and 19. ( D ) LLC1 tumor growth was compared in mice ( n = 8) that received 30μg CpG monotherapy, L82 LP-pulsed DC vaccination (1 × 10 6 ), and CpG, or the triple combination of DC vaccination, CpG, and A2R antagonists. DC vaccines were prophylactically administered twice at a 2-week interval.

Article Snippet: Monoclonal antibodies (mAbs) specific for PD-1 (RMP1-14), CTLA-4 (9H10), CD38 (NIMR5), and CD16/32 (2.4G2) were purchased from BioXcell (Lebanon, NH, USA).

Techniques: RNA Sequencing Assay, Flow Cytometry, In Vitro, Injection

Journal: Cancers

Article Title: Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1

doi: 10.3390/cancers13215508

Figure Lengend Snippet: The triple combination of DC vaccination, CpG and anti-CD38 mAb treatment inhibited LLC1 tumor growth. ( A ) C57BL/6 mice were divided into five groups (five mice per group): (1) 30μg CpG treatment; (2) CpG plus 250μg anti-CD38 mAb; (3) 1×10 6 L82 LP-pulsed DC vaccination with CpG; (4) the triple combination of L82 LP-pulsed DC vaccination, CpG, and anti-CD38 mAb; and (5) the quadruple combination of DC, CpG, anti-CD38 mAb, and 200μg of anti-PD-1 mAb. LLC1 cells (5 × 10 5 ) were subcutaneously inoculated and tumor growth was monitored. ( B ) On day 14, tumor-infiltrating cells were extracted from these mice ( n = 5) and subjected to flow cytometry. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Monoclonal antibodies (mAbs) specific for PD-1 (RMP1-14), CTLA-4 (9H10), CD38 (NIMR5), and CD16/32 (2.4G2) were purchased from BioXcell (Lebanon, NH, USA).

Techniques: Flow Cytometry

Journal: Cell reports

Article Title: High-dimensional profiling clusters asthma severity by lymphoid and non-lymphoid status

doi: 10.1016/j.celrep.2021.108974

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Anti-Human CD38 (HIT2)-172Yb , Fluidigm , Cat# 3172007B; RRID:AB_2756288.

Techniques: Purification, Antibody Labeling, Flow Cytometry, Software, Staining, Blocking Assay